The OTC Monograph Drug User Fee Transparency Act amends the Federal Food, Drug, and Cosmetic Act to elevate transparency around OTC monograph processes. Starting in fiscal year 2026, the FDA must include an annual performance report with progress toward goals, timelines, and postmarket safety activities.
The bill also expands reporting on OTC monograph drug facilities and CMOs, and requires public minutes of FDA negotiation meetings. Separately, GAO must assess the OTC monograph supply chain within two years of enactment.
The overall aim is to increase visibility into regulatory actions, supply chain resilience, and the negotiation process between FDA and industry, while preserving confidentiality where legally required.
At a Glance
What It Does
The bill amends Section 744N to require an annual performance report from the FDA on OTC monograph activities, adds a suite of information to that report starting FY2026, requires facility registration data, and mandates publication of negotiation meeting minutes. It also requires a GAO supply chain assessment.
Who It Affects
OTC monograph drug facilities, contract manufacturing organizations, FDA/CDER staff, industry negotiators, and the public seeking regulatory transparency.
Why It Matters
It creates a formal, data-driven view of OTC monograph activity and supply chain health, potentially speeding accountability and enabling better risk management for manufacturers and consumers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill changes how the FDA reports on OTC monograph activities. It inserts new data requirements into the annual performance report, including counts of various monograph order requests, processing timelines, and postmarket safety work.
It also adds information about the registration status and fees of OTC monograph facilities and CMOs. A new requirement mandates robust minutes from FDA industry negotiations, published publicly within 30 days of meetings.
In addition, the GAO must deliver a report within two years assessing the OTC monograph supply chain, including data collection practices, how information informs regulatory decisions, and coordination with other agencies. Overall, the bill pushes for higher transparency and data-driven oversight of OTC monograph programs, while maintaining confidentiality where legally required.
The Five Things You Need to Know
The bill expands the annual OTC monograph performance report (Section 744N) to start in FY2026.
The report will include counts of Tier 1 and Tier 2 order requests and final orders, plus specified safety orders.
It requires disclosure of OTC monograph facility registrations and CMOs, and whether facility fees were paid.
Negotiation meetings between FDA and industry must have robust, public minutes within 30 days.
GAO must assess the OTC monograph supply chain and regulatory information needs within two years of enactment.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Expanded OTC monograph performance reporting
Section 2(a) broadens the FDA’s annual reporting under Section 744N to include, beginning in fiscal year 2026, a detailed look at progress toward OTC monograph goals and future plans. It moves to a consolidated framework that covers the status of order requests, timelines, and postmarket safety activities, with a focus on data availability and accessibility for oversight and planning.
New data fields in the annual report
The added information includes the numbers of Tier 1 and Tier 2 OTC monograph order requests (proposed and final orders), the status of specified safety and generally recognized as safe and effective (GRASE) order requests, the average processing timelines (overall and by submission type), and postmarket safety activities. It also requires a narrative on how safety data and external databases are used to identify risks and inform regulatory actions, along with activities under section 760.
Confidentiality protections reaffirmed
The new data requirements do not override confidentiality protections. Information that is prohibited from disclosure by statute or exempt from public disclosure remains protected, ensuring that sensitive or proprietary information is not disclosed inappropriately.
Minutes of FDA–industry negotiations
The bill requires robust written minutes of all negotiation meetings between FDA and regulated industry to be made publicly available on the FDA website within 30 days. The minutes must detail substantive proposals, major controversies, and resolutions to ensure accountability and clarity about negotiation positions.
GAO supply-chain assessment mandate
Within two years of enactment, the GAO must report on the OTC monograph drug supply chain. The contents cover overall stability, types of information FDA collects, how that information informs regulatory decisions, coordination with other agencies to mitigate disruptions, and any unique market characteristics that justify additional authorities or information needs.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- OTC monograph drug facilities and contract manufacturing organizations gain clearer expectations and potential predictability in regulatory processes.
- FDA/CDER benefits from structured, centralized data to monitor and optimize OTC monograph regulation and supply-chain risk.
- GAO gains access to a formal data set and reporting channel to assess and oversee the OTC monograph regime.
- Health care providers and pharmacists gain visibility into the supply chain and regulatory timelines, improving patient safety planning.
- Consumer safety groups and researchers obtain more granular public data to analyze regulatory outcomes and safety signals.
Who Bears the Cost
- OTC monograph facilities and CMOs bear reporting and data-management burdens, and some may face new fee disclosures.
- FDA/CDER incur additional costs to compile, standardize, and publish expanded performance data and negotiation-minutes material.
- Industry negotiators invest time and resources to produce detailed minutes and support data disclosures.
- GAO funding requirements and staff time are increased to conduct and publish the supply-chain assessment.
- Small manufacturers could face disproportionate compliance costs due to expanded data-collection requirements.
Key Issues
The Core Tension
Balancing robust, public-facing transparency with the need to protect confidential, commercially sensitive information and maintain orderly, timely regulatory processes.
The bill meaningfully increases government transparency around the OTC monograph program, but that transparency must be balanced against confidentiality and competitiveness. While it enhances data collection, standardization, and public accountability, it also risks exposing negotiation strategies and sensitive business information.
The added reporting demands will require data governance, consistent definitions, and robust data management within FDA. The public-minutes requirement raises questions about the degree to which negotiations with industry can occur off the record and how to safeguard proprietary information while preserving public oversight.
The GAO supply-chain study will hinge on the availability of reliable, comparable data and the ability to translate findings into regulatory actions without creating unintended supply disruptions. Finally, the two-year GAO timeline may constrain immediate regulatory responses in fast-moving OTC markets, even as it provides a longer horizon for systemic insights.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.